Indee Labs publicizes a grant award from the National Institute of Allergy and Infectious Diseases to develop the µVS Delivery SystemTM for modified regulatory T cells
BERKELEY, Calif.–(BUSINESS WIRE)–August 24, 2020–
Indee Labs is a biotechnology firm creating the µVS Delivery SystemTM for non-viral intracellular or gene supply. The staff at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells.
“Cellular immunotherapies using regulatory T (Tregs) cells show tremendous promise for the treatment of autoimmune disease, transplant rejection, and graft-versus-host disease,” mentioned Justin Jarrell, Ph.D., Vice President of Research at Indee Labs. “With funding from NIAID, our goal is to apply our novel, non-viral delivery platform, the µVS Delivery SystemTM, to engineer antigen-specific Tregs and demonstrate their utility as a therapeutic to prevent GvHD in preclinical models and as a scalable alternative to viral- and electroporation-based cell manufacturing.”
The staff at Indee Labs has made a number of developments within the discipline of intracellular supply. Key benefits of μVS embody excessive yield of modified cells with speedy processing of tens of tens of millions of cells in seconds with negligible perturbation of the immune cell state. More element is accessible in Nature Scientific Reports and bioRxiv.
This analysis is being funded by NIAID, NIH, underneath the Small Business Innovation Research Award R43 AI155018.
About Indee Labs
Indee Labs is a seed-stage startup creating the µVS Delivery SystemTM for T cell immunotherapy manufacturing in collaboration with a number of pharmaceutical and biotechnology corporations amongst others. The staff at Indee Labs has already demonstrated revolutionary enhancements over present strategies together with scalability, excessive yield, negligible perturbation of the immune cell state together with speedy processing of research-, clinical- and commercial-scale samples with a easy workflow and a small footprint. Indee Labs is backed by IndieBio/SOSV, Y Combinator, Social Capital, Main Sequence Ventures, Founders Funds’ FF Science amongst others. More data is accessible at indeelabs.com together with Nature Scientific Reports and bioRxiv.
Chief Executive Officer
+1 949 500 6965